Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Simon Udovica"'
Autor:
Maximilian Marhold, Simon Udovica, Anna Halstead, Mona Hirdler, Muna Ferner, Kerstin Wimmer, Zsuzsanna Bago-Horvath, Ruth Exner, Florian Fitzal, Kathrin Strasser-Weippl, Tim Robinson, Rupert Bartsch
Publikováno v:
OncoImmunology, Vol 12, Iss 1 (2023)
ABSTRACTBased upon results of the KEYNOTE-522 trial and following approval by regulatory authorities, the addition of pembrolizumab to chemotherapy is now the standard-of-care for the treatment of early triple-negative breast cancer (eTNBC) (Clinical
Externí odkaz:
https://doaj.org/article/1ff23e6d3c4f4d5ba552842c9e055d6a
Autor:
Simon Udovica, Kathrin Strasser-Weippl
Publikováno v:
memo - Magazine of European Medical Oncology. 16:125-128
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::47a432fb8b62c45760a12aaed7da5e46
https://doi.org/10.1007/s12254-023-00888-z
https://doi.org/10.1007/s12254-023-00888-z
Autor:
Maximilian Marhold, Simon Udovica, Kerstin Wimmer, Zsuzsanna Bago-Horvath, Tim Robinson, Florian Fitzal, Kathrin Strasser-Weippl, Rupert Bartsch
Publikováno v:
Cancer Research. 83:P3-06
Background and Significance: Recently, the addition of the immune checkpoint-inhibitor PEM to CHT was shown to increase pCR rates and invasive event-free survival in the Keynote-522 (KN522) trial. Several irAEs are known to occur during use of PEM in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f4022a811ba400beb84348846eb05dd1
https://doi.org/10.1158/1538-7445.sabcs22-p3-06-10
https://doi.org/10.1158/1538-7445.sabcs22-p3-06-10
Autor:
Clemens Petrasch, Simon Udovica, Frédéric Witte, Bernadette Liegl-Atzwanger, Wolfgang Pokieser, Siroos Mirzaei, Wolfgang Hilbe, Andrea Kaufmann-Keck
Publikováno v:
memo - Magazine of European Medical Oncology. 16:122-124
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5fa64ded459b722754110c1163816004
https://doi.org/10.1007/s12254-023-00880-7
https://doi.org/10.1007/s12254-023-00880-7
Publikováno v:
memo - Magazine of European Medical Oncology. 15:165-168
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::af1981b2d8937e4e8e1636fd3cdb275c
https://doi.org/10.1007/s12254-022-00805-w
https://doi.org/10.1007/s12254-022-00805-w
Autor:
Simon Udovica, Nino Müser, Agnes Pechlaner, Andreas Reichinger, Christoph Aichinger, Kathrin Strasser-Weippl, Holger Rumpold, Andreas Petzer, Ewald Wöll, Wolfgang Hilbe, Ercan Müldür
Publikováno v:
memo - Magazine of European Medical Oncology. 15:153-160
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::40640bc4952a3f58d37ab29833730157
https://doi.org/10.1007/s12254-022-00814-9
https://doi.org/10.1007/s12254-022-00814-9
Autor:
Michael Krainer, Maximilian Marhold, Thais Topakian, Erwin Tomasich, Gerwin Heller, Simon Udovica
Publikováno v:
Translational research : the journal of laboratory and clinical medicine. 230
Loss of hepatocellular carcinoma-related protein 1 (HCRP1) (alias VPS37A) plays a role in endocytosis of receptor tyrosine kinases as a member of the ESCRT complex and has been linked to poor patient outcome in various types of epithelial cancer. To
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0384792dbcb65e572fafff82ddd76e9
https://pubmed.ncbi.nlm.nih.gov/33197651
https://pubmed.ncbi.nlm.nih.gov/33197651
Autor:
Maximilian Marhold, Simon Udovica, Thais Topakian, Peter Horak, Reinhard Horvat, Erwin Tomasich, Gerwin Heller, Michael Krainer
Publikováno v:
Cancers, Vol 14, Iss 749, p 749 (2022)
Cancers; Volume 14; Issue 3; Pages: 749
Cancers; Volume 14; Issue 3; Pages: 749
Targeting testosterone signaling through androgen deprivation therapy (ADT) or antiandrogen treatment is the standard of care for advanced prostate cancer (PCa). Although the large majority of patients initially respond to ADT and/or androgen recepto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d702fd56dd884813ca0ad62ba9da293
https://doi.org/10.3390/cancers14030749
https://doi.org/10.3390/cancers14030749
Autor:
Maximilian Marhold, Simon Udovica, Andreas Heinzel, Peter Horak, Michael Krainer, Paul Perco, Erwin Tomasich, Michael Schwarz, Paul Mayer
Publikováno v:
Scopus-Elsevier
Oncotarget
Oncotarget
In recent years, the concept of synthetic lethality, describing a cellular state where loss of two genes leads to a non-viable phenotype while loss of one gene can be compensated, has emerged as a novel strategy for cancer therapy. Various compounds
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3adae0dc8e991dfa19d9f01ce128284f
https://doi.org/10.18632/oncotarget.26372
https://doi.org/10.18632/oncotarget.26372
Autor:
Erwin Tomasich, Michael Krainer, Akil Merchant, Hossein Taghizadeh, Simon Udovica, Maximilian Marhold
Publikováno v:
OncoImmunology, Vol 8, Iss 11 (2019)
Oncoimmunology
Oncoimmunology
The advancement of immune-therapeutics in cancer treatment has proven to be promising in various malignant diseases. However, in castration resistant prostate cancer (mCRPC) major Phase III trials have been unexpectedly disappointing. To contribute t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::966cf1cd0c8cc5f0fb77215bfcc40c80
https://doaj.org/article/3cf673f895394b8cb2c991707d2e65ec
https://doaj.org/article/3cf673f895394b8cb2c991707d2e65ec